Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marc Steven Sabatine, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. UH3TR000901 (DAS, SAUMYA) Aug 1, 2013 - Jul 31, 2018
    NIH/NCATS
    Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
    Role: Co-Principal Investigator
  2. UH2TR000901 (DAS, SAUMYA) Aug 1, 2013 - Jul 31, 2015
    NIH/NCATS
    Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
    Role: Co-Principal Investigator
  3. R01HL098280 (GERSZTEN, ROBERT E) Mar 15, 2010 - Jan 31, 2015
    NIH/NHLBI
    Metabolomic Biomarkers of Early Myocardial Injury
    Role: Co-Principal Investigator
  4. RC1HL099634 (SABATINE, MARC S) Sep 30, 2009 - Aug 31, 2012
    NIH/NHLBI
    Genetic Risk Stratification to Identify Individuals for Early Statin Therapy
    Role: Principal Investigator
  5. RC1HL099692 (SABATINE, MARC S) Sep 30, 2009 - Aug 31, 2011
    NIH/NHLBI
    Biomarkers of Prognosis and Response to Therapy in Acute Coronary Syndromes
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019 May 22. PMID: 31116355.
    Citations:    
  2. Wiviott SD, Raz I, Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2019 05 09; 380(19):1881-1882. PMID: 31067395.
    Citations:    
  3. Zelniker TA, Jarolim P, Scirica BM, Braunwald E, Park JG, Das S, Sabatine MS, Morrow DA. Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes. J Am Heart Assoc. 2019 May 07; 8(9):e011444. PMID: 31020897.
    Citations:    
  4. Qamar A, Giugliano RP, Sabatine MS. Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. JAMA Cardiol. 2019 May 01. PMID: 31042267.
    Citations:    
  5. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 Apr 23; 139(17):2022-2031. PMID: 30786725.
    Citations:    
  6. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019 May; 21(5):665-675. PMID: 30895697.
    Citations:    
  7. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Ceška R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoglu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 Mar 19; 139(12):1483-1492. PMID: 30586750.
    Citations:    Fields:    
  8. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 May 28; 139(22):2528-2536. PMID: 30882238.
    Citations:    
  9. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 May 28; 139(22):2516-2527. PMID: 30882239.
    Citations:    
  10. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019 Mar; 16(3):155-165. PMID: 30420622.
    Citations:    Fields:    
  11. Bergmark BA, Udell JA, Morrow DA, Jarolim P, Kuder JF, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial. Eur J Heart Fail. 2019 Apr; 21(4):462-470. PMID: 30773798.
    Citations:    
  12. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019 01 29; 321(4):364-373. PMID: 30694319.
    Citations:    Fields:    
  13. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 Jan 15; 139(3):366-375. PMID: 30586726.
    Citations:    Fields:    
  14. Qamar A, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, Wasserman SM, Sever PS, Pedersen TR, Sabatine MS. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA Cardiol. 2019 Jan 01; 4(1):59-63. PMID: 30540337.
    Citations:    Fields:    
  15. Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, Sabatine MS, Mani V, Fayad ZA. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J. 2018 Dec 18. PMID: 30561610.
    Citations:    Fields: